INTRODUCTION
Wiskott --Aldrich Syndrome (WAS) is a fatal X-linked immune deficiency with an abbreviated life-expectancy of 15 --20 years that is characterized by micro-thrombocytopenia, eczema and immune deficiency with autoimmunity and malignancy in more severe phenotypes. 1 --3 Successful hematopoietic cell transplantation (HCT) from a matched sibling donor provides curative treatment and is accepted as the standard of care. 4 Use of alternative donor sources, and particularly T cell-depleted haploidentical donors, has historically been associated with poorer survival. 5 --8 In this study, we report excellent results following unmanipulated unrelated donor HCT in the largest known single center experience of 47 patients with WAS transplanted over a 20-year period. Significant practice changes implemented over the last decade such as high resolution HLA typing, close monitoring of post-transplant donor chimerism, early detection of viral reactivation, and new immunosuppressive agents available for treatment of GVHD have likely contributed to improved survival and decreased complications post-HCT.
SUBJECTS AND METHODS
A total of 47 males diagnosed with WAS underwent HCT at Cincinnati Children's Hospital Medical Center (CCHMC) from 1990 --2009. Permission for review of the patients' medical charts was obtained from the institutional review board. Subjects were divided into two cohorts based on the timing of HCT: 1990 --2000 (n ¼ 16) and 2001 --2009 (n ¼ 31). Analysis of cohorts by transplant decade was used to illustrate improved survival since 2000 as a result of progressive improvements in HCT. In this study, age o2 years was chosen to analyze the impact of younger age on HCT outcome due to equal numbers of patients in each age group: n ¼ 25 and n ¼ 22 patients were o2 and 42 years of age, respectively.
Pre-HCT infections were deemed significant if recurrent or resulted in hospitalization. Serious bleeding complications pre-HCT were defined as recurrent, prolonged, and/or life-threatening hemorrhage requiring platelet transfusions.
HLA typing before 1998 was performed by serological methods for class I and by molecular methods for class II loci. After 1998, highresolution molecular HLA typing was performed at class I and II loci for all patients regardless of donor type. Since 2001, WAS protein (WASP) expression was determined by flow cytometry.
All but one patient received myeloablative conditioning according to current protocols. Before 1996, two patients received irradiation and four received etoposide with combinations of BU, CY, and ATG. After 1996, 30 patients received myeloablative BU (approximately 16 mg/kg total dose), IV CY (200 mg/kg total dose) and anti-thymocyte globlulin (90 mg/kg total dose). Patients received targeted BU after 2004. One patient received a non-myeloablative conditioning regimen (Fludarabine/Melphalan) due to prior intensive chemotherapy for treatment of recurrent lymphoma. All patients received ATG, including patients with a matched related donor. GVHD prophylaxis consisted of cyclosporine and prednisone (1 mg/kg/day) in the majority of patients; before 1996, three patients received short course MTX.
The primary outcomes studied were OS, development of post-HCT complications, immunologic reconstitution, platelet recovery and performance status. Post-transplantation complications analyzed included acute and chronic GVHD (aGVHD and cGVHD), autoimmune cytopenias, mixed chimerism, graft rejection, post-HCT malignancy and viral reactivation. Viral reactivation was assessed by quantitative whole-blood PCR for CMV, EBV and adenovirus in all patients after 2000. Clinical viral screening was performed pre-HCT and at intervals of once to twice a week post-HCT across all age groups and disease categories. Patients were treated for viral reactivation early on before onset of symptomatic disease. The cumulative incidence of aGVHD and cGVHD was calculated using prospectively collected GVHD scores on CIBMTR forms. 9, 10 Mixed chimerism was defined as detectable host cells 410% but o95% in the peripheral blood by FISH or STR method. In the majority of patients, whole blood rather than lineage-specific chimerism was historically followed. Performance status was assessed using Lanksy/Karnofsky performance scores (LPS/KPS). Surviving patients were censored at the last follow-up.
The probability of OS and its 95% confidence interval were calculated using the Kaplan --Meier estimator and associated confidence interval method. 11 Cox regression analysis was used for multivariate analysis of risk factors for OS to determine the contribution of each variable.
12,13 Age, transplant era, level of HLA mismatch, and their first-order interactions were considered in the multivariate model. A P-value p0.05 was considered statistically significant. The proportional hazards assumption of the model was determined. A competing risk model was used to calculate and compare the cumulative incidence rate of acute and chronic GVHD accounting for death as a competing event.
14 Medians were computed for continuous variables. Proportions were computed for dichotomous variables and compared using the w 2 or Fisher's exact test. All reported P-values are two-sided. WASP gene mutation data was available in 38 patients ( Table 2 ). Data were not available in nine patients; no mutation was detected in one patient (#20) with the clinical phenotype and absent WASP (Wiskott --Aldrich Syndrome protein) expression by western blot. WASP expression in hematopoietic cells was dim to absent in all but one patient tested (n ¼ 28) ( Table 2) .
RESULTS

Pre
Patient and transplant characteristics for all 47 patients are listed in Table 3 . The median age at HCT was similarly young in both decades (P ¼ 0.24). Donor type by transplant decade is described in Table 4 . The majority of patients from each transplant era received BM. Since 2000, the number of adult unrelated donors increased from 9/16 (56%) to 22/31 (71%), although this was not statistically significant (P ¼ 0. OS was compared by age and transplant era and differed significantly among the four groups (log-rank test, P ¼ 0.02) (Figure 1b) . In multivariate analysis, the era of HCT was significant (P ¼ 0.04) with an HR of 4.4, age at HCT was marginally significant (P ¼ 0.06), and the number of HLA mismatches at the allele or Ag level was not significant (P ¼ 0.64) ( Table 5 ).
Death occurred in nine patients following HCT ( Table 6 ). The major cause of death was infection. More deaths (n ¼ 6) occurred among patients transplanted during 1990 --2000, and all occurred within 6 months post-HCT. Deaths due to sepsis in the context of GVHD were observed in both eras. During 2001 --2009, 3 deaths occurred. Causes of death in each case were sepsis in the setting of cGVHD, GI hemorrhage while an outpatient, and multi-organ failure, respectively. The third patient was discharged in good condition to his home institution but deteriorated at the local hospital with progression to respiratory failure of unknown origin and multi-organ failure. The median time to death was 110 days and 1100 days for patients transplanted during 1990 --2000 and 2001 --2009, respectively. Mortality tended to occur in older patients; 7/9 patients who died were 42 years at the time of HCT.
The incidence of aGVHD (grades II --IV) did not differ by transplant decade at 50% (95% CI: 23% --72%) and 35% (95% CI: The incidence of cGVHD did not differ by transplant decade at 12.5% (95% CI: 1.8 --34%) and 36.8% (95% CI: 14.6 --59.5%) in the 1990 --2000 and 2001 --2009 groups, respectively (P ¼ 0.22). The incidence of cGVHD did not differ by level of HLA match with an incidence of 26.2% (95% CI: 7.8 --49.5%) compared with 30.6% (95% CI: 10.1 --54.3%) in patients with HLA-identical and 1 --2 HLA loci-mismatched donors, respectively (P ¼ 0.65). Overall, six patients developed limited cGVHD, which resolved in all cases. Four patients developed extensive cGVHD: one has died of candidemia, whereas the other three continued treatment and two are improving.
Three patients (#13, 19 and 20) developed complete graft rejection following transplantation; two of whom received T-depleted grafts (both before 2000). Patient no. 13 initially received an unmanipulated 6/6 matched-related donor (MRD) (mother) HCT at 15 years of age, followed by complete graft rejection with marrow aplasia in the setting of EBV viremia. He died from overwhelming EBV PTLD only 7 days after receiving a boost of maternal CD34 þ cells at 156 days from initial HCT. Patient no. 19 is doing well with 100% donor chimerism and a Lansky score of 100% following a second transplant from a different 6/6 matched urelated donor (MUD) donor. Patient no. 20 died with extensive cGVHD following a second transplant from a different 6/6 MUD donor. None of the eight patients who received a UCB transplant experienced graft rejection.
Mixed donor chimerism was treated in five patients with additional DLI or CD34 þ cells from the original donor. One patient (no. 8) experienced progressive decline in engraftment from 31 to 20% despite DLI x 2 with recurrence of microthrombocytopenia. He subsequently underwent a second myeloablative HCT with the same sibling donor that resulted in post-HCT engraftment of 96 --100% donor cells and an LPS/KPS of 100%. Three patients (no. 14, 32 and 40) received unmanipulated DLI for mixed chimerism with subsequent sustained increase in donor chimerism from 40 to 64% (no. 14), 61.5 to 92% (no. 32), and 55 to 88% (no. 40), respectively. Patient no. 16 received a CD34 þ cell infusion for mixed chimerism. He had undergone a splenectomy pre-HCT and received a 6/6 MUD donor T-cell depleted product at 1.5 years of age. Mixed chimerism developed within 3 months of HCT with 72.4% donor cells and gradually declined over the first year and ranged between 1.8 --11.4% over the next 5 years. WASP expression was also chimeric with normal expression in 64% of lymphocytes, 37% of neutrophils and 50% of monocytes. He received a PBSC-derived CD34 þ cell selected boost with a CD3 þ cell dose of 1 Â 10 4 cells/kg from his original donor without preconditioning. Donor chimerism subsequently improved to 41% over the following 3 years. He now has a predominance of donor cells in his lymphocyte compartments, and maintains normal lymphocyte counts, normal Ag-directed responses, normal Tregs and normal NK function. Clinically, he continues to do well with an LPS/KPS of 100% and a normal platelet count, but does have autologous B-cell recovery and remains on intravenous immunoglobulin (IVIG).
The incidence of post-HCT viral reactivation was analyzed by age and transplant era (Table 7) . Among patients transplanted during 2001 --2009, 26/31 (84%) of patients demonstrated one or more positive viral PCR results indicative of viral reactivation. Among patients who were transplanted at a young age (o2 years of age), 12/17 patients (71%) had viral reactivation post-HCT compared with 14/14 older patients (100%), (Fischer's exact test, P ¼ 0.048). Post-HCT EBV-associated PTLD was diagnosed in 2/47 patients (4.3%), 1 of whom survived, and is well 10 years later. Both cases occurred before the widespread use of Rituximab as treatment. Two patients who received UCB transplants before 2000 died of systemic adenoviral infection confirmed at autopsy.
Five patients underwent splenectomy pre-HCT and all experienced significant complications. Two patients demonstrated autoimmune cytopenias pre-transplant; two experienced lifethreatening sepsis pre-transplant and one died post-transplant as a result of sepsis and EBV þ PTLD. (Tables 8a and b) . In all, 17 of 31 patients (55%) had clinical cytopenias diagnosed by detection of relevant autoantibodies. Tri-lineage, dual and single cytopenias were detected in 1/31 (3%), 8/31(26%) and 8/31(26%) patients, respectively. The most common cytopenia detected was thrombocytopenia in 13/31 (42%) of patients (Table 8a) . Median time for diagnosis of immune-mediated cytopenias was 148 days (range 33 --467days), and typically occurred within the first 6 months post-HCT (Table 8b ). The occurrence of autoimmune cytopenias did not correlate with the presence of aGVHD (grades II --IV, P ¼ 0.71), cGVHD (P ¼ 0.12), or mixed chimerism (P ¼ 0.50, all Fisher's exact test) ( Table 9 ). In all, 14 of 17 patients developed auto-Abs independent of cGVHD. Overall, 2 of 16 patients had mixed chimerism of 78.6 and 87% donor cells at the time of autoAb detection; 1 patient without chimerism data. Donor chimerism at the time of last follow-up was X98% in 15/16 patients.
Autoimmune cytopenias resolved in the majority of patients with complete resolution in 11/17 (65%) and ongoing improvement in four patients. The median time to recovery of normal blood counts in this group was 429 days (range 131 --979 days) from the time of HCT.
Manifestations of WAS, such as immune deficiency, thrombocytopenia, eczema and WASP expression improved in the majority of patients post-HCT. Immune function was assessed in surviving patients who were at least 2 years post-HCT and of all immunesuppressive therapy (Table 10 ). A total of 27 patients met these criteria. Post-HCT, response to mitogen stimulation, lymphocyte subpopulations, and NK cell function were normal in 22/27 (81%), 21/27 (78%) and 21/27 (78%) of patients, respectively. Dysgammaglobulinemia also improved in the majority of patients. Post-HCT IgM, IgA and IgE levels were normal in 22/27 (81%), 21/27 (78%) and 19/27 (70%) of patients, respectively. All patients are currently off prophylactic antibiotics and remain free of patients transplanted during 2001 --2009 had a LPS/KPS o80. One patient remains on treatment for cGVHD, and one is receiving treatment for thrombotic microangiopathy of transplant. The third patient had a very large deletion in the WASP gene resulting in progressive demyelination and infantile seizures pre-HCT. Post-HCT, the patient had no significant transplant-related complications, but died as a result of progressive neurologic deficits.
DISCUSSION
This study represents the largest single institution report of HCT outcomes for patients with WAS. We demonstrate improved 5-year OS for all patients transplanted in the last decade. The increased number of patients transplanted in the last decade reflects the increased utilization of alternative donor sources for treatment of this disease, and improvements in outcomes can be attributed to progressive improvements over the last decade in the care of HCT patients. Moratto et al. 15 also report improved survival post-2000 and similarly attribute this to improved selection of unrelated donors with high-resolution HLA-typing, improved viral monitoring, especially for EBV and lymphoproliferative disease, and use of additional immunosuppressive drugs resulting in reduced graft rejection and additional agents for GVHD treatment.
Young age at HCT, age o2 years, had a marginally significant impact on 5-year OS in multivariate analysis and supports the case for early transplantation before development of more severe manifestations of WAS, such as autoimmunity and malignancy. Moratto et al. also report improved survival following HCT in patients who are o2 years of age (91.9% vs 73.3% for patients transplanted at o2 years of age vs those 45-year-old; Po0.05).
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In addition to improved survival, the incidence of severe acute GVHD has decreased. This may be due to use of allele level HLA typing and/or related to changes in therapy such as the wider use of additional immune-suppressive agents, such as monoclonal antibodies against TNFa and CD25, in addition to steroids and calcineurin inhibitors that have improved GVHD outcomes.
Historically, myeloablative conditioning has been used to overcome the engraftment barrier. Even so, a small percentage of patients still experience graft rejection with autologous recovery, particularly in the setting of T-cell depletion. Additionally, all patients who received a T-cell depleted product developed mixed chimerism. Descriptively, these complications were relatively uncommon, and T-cell depletion has been infrequently used after 2000.
Viral reactivation can be a severe, prolonged complication following HCT. 6 --8 In the post-2000 era, early detection using PCR techniques has allowed prompt diagnosis and treatment of reactivated viruses. Not surprisingly, all patients 42 years of age demonstrated viral reactivation post-HCT. Autoimmune cytopenias have been reported to occur in up to 72% of WAS patients following HCT. 3 Approximately, 50% of patients in this study developed an auto-Ab to at least one hematopoietic cell lineage. Time to onset was variable, but most occurred within the first 6 months post-HCT. Time to resolution was also variable, ranging up to 2 years. Therapies used included Rituximab, high-dose IVIG and in selective rare cases, plasmapheresis.
The mechanism for post-HCT autoimmune cytopenias remains undetermined. Persistence of host B lymphocytes and plasma cells have been hypothesized to have a role. Residual host B lymphocytes/plasma cells could remain undetected by studies of peripheral blood chimerism and persist for months post-HCT. The early detection of auto-Abs post-HCT in this series supports a hypothesis involving long-lived residual host plasma cells that tend toward auto-Ab production.
In 2008, Ozsahin et al. 16 reported the finding of autoimmunity independent of chronic GVHD but significantly associated with mixed/split chimerism post-HCT. In contrast to that report in which data was collected retrospectively in questionnaires to multiple transplant centers, data from this study was collected prospectively for any patient developing cytopenia and was analyzed using primary source documentation. In this series, autoimmune cytopenia was not associated with mixed chimerism. However, given the small number of patients that developed mixed chimerism, this result must be interpreted with caution. Importantly, with the current practices of surveillance for autoimmune cytopenias and effective therapy, this complication can be controlled and permanently reversed.
Full immune reconstitution, hematologic recovery with normal WASP expression, and excellent performance status post-HCT were observed in the majority of patients in this series. These findings clarify the benefits of HCT in young patients with WAS who have suitably matched donors, before additional viral exposure and progression to a more severe clinical phenotype.
